Opinion: Let the Market Dictate Drug Prices in China
Listen to the full version
China’s State Council recently issued new guidelines titled Several Opinions on Improving the Market-Driven Drug Pricing Mechanism. This directive dictates that the market should play the decisive role in resource allocation, while sharpening the government’s regulatory function. By proposing reforms across the entire life cycle, distribution channel and sector of the pharmaceutical industry, the policy seeks to invigorate market dynamics, maintain fair competition and act as a catalyst for growth — particularly for developers of innovative therapies. The aim is to foster a high-quality pharmaceutical sector while ensuring the public has access to premium, affordable drugs.
Unlock exclusive discounts with a Caixin group subscription — ideal for teams and organizations.
Save an extra $50. Introductory offer for new readers. Subscribe now.
- DIGEST HUB
Digest Hub
Back
- China's State Council issued guidelines for market-driven drug pricing, emphasizing market allocation, government regulation, innovation, competition, and affordable drugs.
- Reforms since 2015 spurred growth; China holds ~1/3 of global innovative drugs in development, >200 approvals in 14th Five-Year Plan, $130B+ overseas deals in 2025.
- 14 measures optimize pricing for innovative drugs, introduce self-assessment, and use insurance negotiations for value-based, accessible pricing.
1. China's State Council issued "Several Opinions on Improving the Market-Driven Drug Pricing Mechanism," emphasizing market's decisive role in resource allocation and government's sharpened regulation across the pharmaceutical industry's life cycle, distribution, and sectors to boost dynamics, fair competition, growth for innovative therapies, high-quality sector, and affordable premium drugs [para. 1].
2. In 2015, the National Development and Reform Commission and six departments mandated market competition for actual transaction prices (excluding narcotics and Class I psychotropics), alongside drug review overhaul, accelerating China's innovative pharmaceutical sector [para. 2].
3. The 2018 National Healthcare Security Administration establishment made insurance payments key for guiding prices, leading to reductions for domestic breakthrough therapies in and out of insurance, benefiting more patients; new guidelines address concerns by aligning efficient market with proactive government—supporting, protecting, and governing as needed [para. 3].
4. Prices act as "batons" directing innovation beyond supply-demand signals; reforms ensure novel treatments' costs reflect clinical value, creating self-sustaining, evolving ecosystem [para. 4].
5. China's drug innovation has surged from generics to original innovation, holding ~1/3 of global innovative drugs in development, with oncology stars; >200 innovative drugs approved in 14th Five-Year Plan; 2025 overseas licensing deals topped $130 billion [para. 5].
6. Boom validates market-led pricing; guidelines refine policies in key segments, promote price discovery, keep critical prices reasonable, strengthen governance, focusing on clinical value and accessibility [para. 6].
7. Top of 14 measures: optimize initial pricing for new innovative drugs, distinguishing highly innovative, modified new, off-patent generics with tailored support; for top-tier (novel, high-value), support prices reflecting investments/risks, with price stability period [para. 7].
8. Encourages diversified payments and rational pricing for accessibility and drugmaker sustainability, advancing China to global innovation powerhouse [para. 8].
9. Novel therapies' premiums must face real-world scrutiny; introduces self-assessment for price adjustments based on outcomes post-launch, filtering for true innovation [para. 9].
10. Uses medical insurance standards to guide prices, balancing basic insurance, patient welfare, breakthroughs; negotiations for inclusion consider initial price rationality, fund affordability, macroeconomics, clinical value; expands multi-tier insurance and commercial coverage [para. 10].
11. Market-led pricing reform is systemic, needing cross-sector coordination; 15th Five-Year Plan (2026-2030) optimizes urgent drug approvals, commercial insurance for breakthroughs; balances innovation subsidies and affordability, rooting out failures like high prices, kickbacks; aims for accessible, reasonable essential drugs [para. 11].
- MOST POPULAR
Sign in with Google
Sign in with Facebook
Sign in with 财新